Bio-Rad Reports First-Quarter 2016 Currency-Neutral Revenue

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Bio-Rad Reports First-Quarter 2016 Currency-Neutral Revenue Growth of Nearly 4 Percent

HERCULES, CA--(Marketwired - May 5, 2016) - Bio-Rad Laboratories, Inc. ( NYSE : BIO ) and (NYSE: BIO.B), a global provider of life science research and clinical diagnostic products, announced financial results today for the first quarter ended March 31, 2016.

First-quarter 2016 reported revenues were $471.2 million, down 0.3% compared to $472.8 million reported for the first quarter of 2015. On a currency-neutral basis, quarterly revenues increased 3.9% compared to the same period last year. First-quarter 2016 gross margin was 56.0% compared to 57.1% during the same quarter last year. The decrease in gross margin during the first quarter of 2016 was primarily the result of less favorable manufacturing variances compared to the same period last year. 

Net income for the first quarter of 2016 was $12.3 million, or $0.42 per share on a fully diluted basis, compared to $17.8 million, or $0.61 per share during the same period last year. The decrease in net income was largely attributed to lower margins mentioned above as well as an increase in research & development expense. 

The effective tax rate for the first quarter of 2016 was 39%, compared to the 33% tax rate for the same quarter in 2015. The higher tax rate in 2016 was due to certain foreign losses for which no benefit is expected and increased reserves for foreign tax audits.

"We are pleased with the good sales performance in this first quarter," said Norman Schwartz, Bio-Rad President and Chief Executive Officer. "The growth of our Life Science business, at close to 10%, is a very encouraging start for the year."

Life Science The Life Science segment net sales in the first quarter of 2016 were $165.9 million, an increase of 6.4% compared to the same period last year. On a currency-neutral basis, Life Science segment sales increased 9.8% compared to the first quarter in 2015. The sales increase for the first quarter benefitted from sales of our Droplet Digital™ PCR and process media products. In January, Bio-Rad and Illumina, Inc. ( NASDAQ : ILMN ) announced an exclusive partnership to develop the most comprehensive next-generation sequencing (NGS) workflow for single-cell analysis. The end-to-end commercial solution will enable high-throughput sequencing of thousands of individual cells, traditionally a challenging, costly, and time-consuming process. Also during the first quarter of 2016, Bio-Rad acquired a high performance analytical flow cytometer platform from Propel Labs that will enable advanced and novice users to perform basic and multi-parameter cytometry for a wide range of applications and chemistries. Bio-Rad expects to launch the instrument later this year.

Clinical Diagnostics  Net sales for the Clinical Diagnostics segment in the first quarter of 2016 were $301.7 million, a decrease of 3.8% compared to the first quarter of 2015. On a currency-neutral basis, Clinical Diagnostics sales increased 0.9% compared to the same period last year. Results from the first quarter reflected modest growth across most product lines, most notably clinical immunology, quality controls, and diabetes products. In February, the Company announced it had received CE IVD marking for its QX200™ Droplet Digital™ PCR (ddPCR™) System, the first digital PCR system with the CE IVD mark for use as an in vitro diagnostic (IVD) in the European Union. With the CE IVD mark, medical practitioners in Europe can use the QX200 system for highly-accurate detection and quantification of nucleic acids, aiding clinical decision-making in the treatment of diseases ranging from cancer to transplant rejection and viral infection.

Management will discuss these results in a conference call at 2 PM Pacific Daylight Time (5 PM Eastern Daylight Time) May 5, 2016. Interested parties may access the call at 855-779-9068 within the U.S. or 631-485-4862 outside the U.S., passcode: 89354960. You may also listen to the conference call live via a webcast that is available on the "Investor Relations" section of our website under "Quarterly Results" at www.bio-rad.com . The webcast will be available for up to a year. 

About Bio-Rad Bio-Rad Laboratories, Inc. ( NYSE : BIO ) and ( NYSE : BIO.B ) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs more than 7,800 people worldwide and had revenues exceeding $2 billion in 2015. For more information, please visit www.bio-rad.com .

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our release of new products, the growth of our business and future financial performance. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, foreign currency exchange fluctuations, difficulties in implementing our global enterprise resource planning system, our ability to compete effectively, product quality and liability issues, supply chain issues, our ability to realize anticipated benefits from acquisitions, reductions in government funding or capital spending of our customers, international legal and regulatory risks, recent changes to our global organizational structure and executive management team, changes in the healthcare industry, global economic conditions, and natural disasters and other catastrophic events beyond our control. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's public reports filed with the Securities and Exchange Commission (the "SEC"), including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2015, and its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2016 to be filed with the SEC. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements.

   
Bio-Rad Laboratories, Inc.  
Condensed Consolidated Statements of Income  
           
(in thousands, except per share data)  
(UNAUDITED)  
           
           
           
           
  Three Months Ended March 31,  
  2016     2015  
Net sales $ 471,197     $ 472,821  
  Cost of goods sold   207,168       202,715  
Gross profit   264,029       270,106  
               
  Selling, general and administrative expense   189,716       188,555  
  Research and development expense   48,586       47,202  
Income from operations   25,727       34,349  
               
  Interest expense   5,580       5,002  
  Foreign currency exchange losses, net   1,129       3,806  
  Other (income) expense, net   (1,177 )     (1,153 )
Income before income taxes   20,195       26,694  
               
  Provision for income taxes   (7,919 )     (8,876 )
Net income $ 12,276     $ 17,818  
               
Basic earnings per share:              
  Net income per basic share $ 0.42     $ 0.61  
               
  Weighted average common shares - basic   29,364       29,092  
               
Diluted earnings per share:              
  Net income per diluted share $ 0.42     $ 0.61  
               
  Weighted average common shares - diluted   29,506       29,289  
                 
                 
                 
Bio-Rad Laboratories, Inc.
Condensed Consolidated Balance Sheets
 
(In thousands)
 
       
       
       
  March 31,   December 31,
  2016   2015
  (UNAUDITED)    
Current assets:          
  Cash and cash equivalents $ 403,615   $ 457,549
  Short-term investments   349,255     332,928
  Accounts receivable, net   381,100     391,485
  Inventories, net   533,312     490,224
  Other current assets   107,982     105,410
    Total current assets   1,775,264     1,777,596
           
Property, plant and equipment, net   449,226     437,690
Goodwill, net   509,582     495,948
Purchased intangibles, net   242,264     214,026
Other investments   711,437     719,840
Other assets   65,640     64,618
    Total assets $ 3,753,413   $ 3,709,718
           
Current liabilities:          
  Accounts payable, accrued payroll and employee benefits $ 241,249   $ 280,248
  Current maturities of long-term debt   296     298
  Income and other taxes payable   27,725     29,339
  Other current liabilities   131,618     131,466
    Total current liabilities   400,888     441,351
           
Long-term debt, net of current maturities   433,980     433,883
Other long-term liabilities   374,096     343,981
    Total liabilities   1,208,964     1,219,215
           
    Total stockholders' equity   2,544,449     2,490,503
    Total liabilities and stockholders' equity $ 3,753,413   $ 3,709,718
               
               
               
Bio-Rad Laboratories, Inc.  
Condensed Consolidated Statements of Cash Flows  
   
(In thousands)  
(UNAUDITED)  
             
             
             
             
    Three Months Ended March 31,  
             
    2016     2015  
                 
Cash flows from operating activities:                
  Cash received from customers   $ 492,407     $ 478,479  
  Cash paid to suppliers and employees     (508,820 )     (453,986 )
  Interest (paid) received, net     (187 )     471  
  Income tax refunds     10,421       1,503  
  Other operating activities     (1,269 )     2,979  
  Net cash (used in) provided by operating activities     (7,448 )     29,446  
                 
Cash flows from investing activities:                
  Payments for acquisition and long-term investment     (9,634 )     (895 )
  Other investing activities     (41,224 )     (27,096 )
  Net cash used in investing activities     (50,858 )     (27,991 )
                 
Cash flows from financing activities:                
  Payments on long-term borrowings     (77 )     (66 )
  Other financing activities     335       (265 )
  Net cash provided by (used in) financing activities     258       (331 )
                 
Effect of foreign exchange rate changes on cash     4,114       11,353  
                 
Net (decrease) increase in cash and cash equivalents     (53,934 )     12,477  
Cash and cash equivalents at beginning of period     457,549       413,251  
Cash and cash equivalents at end of period   $ 403,615     $ 425,728  
                 
                 
Reconciliation of net income to net cash                
provided by operating activities:                
Net income   $ 12,276     $ 17,818  
Adjustments to reconcile net income to net cash                
provided by operating activities:                
    Depreciation and amortization     34,090       32,283  
    Changes in working capital     (63,730 )     (20,619 )
    Other     9,916       (36 )
Net cash (used in) provided by operating activities   $ (7,448 )   $ 29,446  
                 

Investor and Financial Contacts: Bio-Rad Laboratories, Inc. Christine Tsingos Executive Vice President and Chief Financial Officer Ron Hutton Vice President, Treasurer 510-724-7000 Email Contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 132

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading
Zettia R. Barnes: Charting a Path in Home Healthcare

Updated Category News Views 146

The Lifeline of Home Healthcare in DeSoto You know, it ain't every day that someone like Zettia R. Barnes steps up in the realm of home healthcare and makes a mark that genuinely sticks. From rubbing shoulders with patients to steering a whole dang organization like Angels of Hands Home Health Agency Corp., she's got her hands full—and frankly, it’s folks like her who...

Continue Reading
Biotech Hit or Miss: Trials and Tribulations

Updated Category News Views 96

Biotech's Roller Coaster: Triumphs and Setbacks Ah, the biotech sector—it's a bit like jumping on a bull, ain't it? You barely hang on when the beast bucks. Monday's market action was downright wild. The S&P 500 didn't have a party, tumbling 1.92%, and the Nasdaq wasn't any friendlier, plummeting 2.49%. Yet, inside this storm, we see some biotech names either catching...

Continue Reading
Austin Rattler Event Revamps With Two-Day Off-Road Bash

Updated Category News Views 42

Austin's Off-Road Bash Kicks Up Dust in Hill Country It's not just another grind in the biking and running world; the Life Time Austin Rattler's gone off the reservation pushing the pedals and the pace across the rugged terrain of Texas Hill Country. Here's to muscles burning and soles slapping the dirt for two straight days, all in the name of challenging nature's best....

Continue Reading
Exploring Creation: A Fresh Look at Genesis

Updated Category News Views 67

Opening Up Genesis in a New Light Hey, if you’re like most folks, you’ve probably heard Genesis framed as the battleground for science versus religion debates, right? Enter into this mix a fresh take with Robert E. Franzen’s new book, The Narration of Creation. This book asks you to overlook those grand philosophical fights and instead focus on the narrative itself....

Continue Reading
Hermes AI: A New Era in Market Analysis?

Updated Category News Views 111

Revolution or Just Another App? In a world where stock market insights are as cryptic as hieroglyphs to the average Joe, here comes the Hermes AI Analyzer, breaking onto the scene and promising to translate Wall Street's complex lingo into plain, simple language. It's the brainchild of Turkish engineer Umut Tugrul, who has spent decades in the trenches of software...

Continue Reading
Giovanni Recalde Sues County After False Report

Updated Category News Views 153

Justice and Reputation: A Mix-Up Costs Big When the cops screw up, sometimes they really take the cake. That's what Giovanni Recalde learned, the hard way, when his name got tangled in a mess related to a gambling operation he wasn't even a part of. Prince William County police pasted his name into their daily incident report last year like it was no big deal. But it...

Continue Reading
Rakuten Medical Fires Up Phase 1 Trial for RM-0256 Therapy

Updated Category News Views 219

Taking Aim at Refractory Tumors in Japan Get this—Rakuten Medical is stepping into the ring with their new cancer-busting tactic, RM-0256 photoimmunotherapy, right in Japan. We're talking about a Phase 1 trial that'll throw a new kind of punch at solid tumors, specifically targeting troublesome skin cancers that don’t seem to play nice with current treatments. Now,...

Continue Reading
Mars Moves on Cash Tender Offers for Seniors' Notes

Updated Category News Views 197

A Strategic Financial Maneuver or a Casual Gambit? Okay, what’s Mars up to now, you ask? Here we go with this. The behemoth behind some of your favorite snacks and pet indulgences is making waves—not with candy, but with cash. Mars, Incorporated is rolling out tender offers to buy back a substantial chunk of its Senior Notes for $2 billion in cold, hard cash. When a...

Continue Reading
Main Capital Partners Backs TaskRay: Salesforce Expansion

Updated Category News Views 118

Investing in Transformation Main Capital Partners has thrown in with TaskRay, joining hands with Cloud Coach and JustOn to shake up customer delivery on Salesforce. These three are cooking up an ambitious AI-driven platform that's gunning to streamline from project management to financial operations. Main's stepping into this mix with a mindset that aligns with over 800...

Continue Reading

Top 5 Most Recently Viewed Articles

Empowering Organizations: RockDove Solutions on Crisis Communication

Updated Category News Views 111

Understanding the Importance of Crisis Communication Plans In today's fast-paced world, effective crisis communication is more critical than ever for businesses. Surprisingly, fewer than half of U.S. companies have formal crisis communication strategies in place. This statistic highlights a significant gap in business continuity planning, where communication often...

Continue Reading
Hafnia Limited Reports Strong Earnings for Q3 2024 Period

Updated Category News Views 83

Hafnia Limited Reports Strong Earnings for Q3 2024 Period Hafnia Limited (“Hafnia” or “the Company”, OSE ticker code: “HAFNI”, NYSE ticker code: “HAFN”), a premier product tanker company with an extensive and modern fleet exceeding 130 vessels, has recently reported promising financial results for the three and nine months ended September 30, 2024. Key...

Continue Reading
Recent Shareholding Changes at Irish Continental Group PLC

Updated Category News Views 138

Understanding Director and PDMR Shareholding Notifications In the world of corporate governance, transparency plays a crucial role in maintaining trust, particularly when it comes to senior management and directors. Recent notifications reveal key transactions involving persons discharging managerial responsibilities (PDMRs) at Irish Continental Group plc. Overview of...

Continue Reading
Experience the Summer Vibes at Coastal Mississippi Events

Updated Category News Views 220

Summer Events in Coastal Mississippi Come Play Coastal all summer long with seafood feasts, fireworks, car shows, and more! Ready to turn up the fun this summer? Coastal Mississippi is bringing a thrilling lineup of unforgettable events, all set against the backdrop of 62 miles of beautiful shoreline. From fresh seafood to electrifying fireworks, sensational car shows,...

Continue Reading
GUNNAR Optiks and 2K Games Unveil Exciting New Glasses

Updated Category News Views 197

GUNNAR Optiks Partners with 2K Games for New Glasses GUNNAR Optiks, a frontrunner in combating digital eye strain and a pioneer in blue light blocking eyewear, has teamed up with 2K Games to introduce an exciting new collection inspired by the much-anticipated Borderlands 4. This striking collection unveils its first eyewear style, aptly named the Ripper, marking the...

Continue Reading